Kristina Wadley
Primary Care · Kennett, MONPI 1124741715
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 176 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 18.5% — the pattern of someone who eats at a lot of different presentations.
Across 176 payments — averaging $18.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$600
- Amgen$489
- Otsuka America Pharmaceutical, Inc.$336
- Sumitomo Pharma America, Inc.$330
- Novo Nordisk$185
- Lundbeck LLC$179
- plus $1K from 25 others
What the payments were for
- Food & beverage$3,20899%
- Education$381%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 29 | $600 |
| Amgen | 33 | $489 |
| Otsuka America Pharmaceutical, Inc. | 15 | $336 |
| Sumitomo Pharma America, Inc. | 20 | $330 |
| Novo Nordisk | 9 | $185 |
| Lundbeck LLC | 9 | $179 |
| AstraZeneca | 9 | $146 |
| Bayer | 8 | $133 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $82 |
| Merck | 4 | $76 |
| Indivior Inc. | 3 | $67 |
| Dexcom, Inc. | 4 | $66 |
| E.r. Squibb & Sons, L.L.C. | 3 | $62 |
| Corcept Therapeutics | 2 | $53 |
| Boehringer Ingelheim | 2 | $38 |
| Astellas Pharma US Inc | 2 | $35 |
| GSK | 2 | $33 |
| Novartis | 2 | $32 |
| Lilly USA, LLC | 2 | $32 |
| Axsome Therapeutics, Inc. | 1 | $30 |
| Amneal Pharmaceuticals LLC | 2 | $30 |
| Vanda Pharmaceuticals Inc. | 2 | $29 |
| Mylan Specialty L.p. | 1 | $28 |
| Neurocrine Biosciences, Inc. | 1 | $26 |
| AbbVie | 1 | $22 |
| Teva Pharmaceuticals USA, Inc. | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Viatris Specialty LLC | 1 | $19 |
| Paratek Pharmaceuticals, Inc. | 1 | $16 |
| Johnson & Johnson | 1 | $15 |
| Scilex Pharmaceuticals Inc. | 1 | $15 |
How this compares
$3,246 in reported general payments places this provider in the 85th percentile of 106 primary care providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 62 | $91,951 |
| TrulicityDulaglutide | 84 | $84,706 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 116 | $79,275 |
| OzempicSemaglutide | 79 | $76,953 |
| MounjaroTirzepatide | 68 | $72,395 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 97 | $66,799 |
| FarxigaDapagliflozin Propanediol | 92 | $54,597 |
| EliquisApixaban | 87 | $50,389 |
| VraylarCariprazine Hcl | 31 | $46,012 |
| LinzessLinaclotide | 82 | $45,864 |
| JanuviaSitagliptin Phosphate | 70 | $42,418 |
| SymbicortBudesonide/Formoterol Fumarate | 190 | $41,651 |
| RybelsusSemaglutide | 36 | $34,738 |
| EntrestoSacubitril/Valsartan | 54 | $32,514 |
| GemtesaVibegron | 42 | $21,775 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort, Brilinta | $146 | $170,677392 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $32 | $157,101152 claims |
| Novo NordiskOzempic, Rybelsus | $185 | $111,690115 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $336 | $91,95162 claims |
| AbbVieVraylar, Linzess | $22 | $91,876113 claims |
| GSKTrelegy Ellipta | $33 | $79,275116 claims |
| MerckJanuvia | $76 | $42,41870 claims |
| NovartisEntresto | $32 | $32,51454 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $330 | $21,77542 claims |
| Boehringer IngelheimJardiance | $38 | $19,73033 claims |
| Johnson & JohnsonXarelto | $15 | $8,99716 claims |
| Astellas Pharma US IncMyrbetriq | $35 | $5,08211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 106 primary care providers in Missouri.
Other primary care in Kennett
- Danielle ToalCape Girardeau$15K
- Joy MurphySaint Louis$7K
- Katrina SelsorSparta$6K
- Kelly EspositoSaint Louis$6K
- Elizabeth YoungSaint Louis$5K
- Carol HarringtonIndependence$4K
- Melanie HenryHayti$4K
- Heather BealSaint Louis$4K
- Taylor HeathSparta$3K
- Ashley TitchenalSaint Louis$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.